Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States.
infoAileron Therapeutics is a micro cap stock with a total market cap of 7.13M.
infoThey trade on the NASDAQ and had their IPO 6 years and 1 month ago.
infoAileron Therapeutics currently employs 6 people.
infoAs of Wednesday, Aug 23 2023, Aileron Therapeutics’s share price is $1.569.
News Relating to Aileron Therapeutics
Zacks Investment Research
Bears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here’s Why It’s a ‘Buy’ Now
Tuesday Apr 04 2023 at 11:24
After losing some value lately, a hammer chart pattern has been formed for Aileron Therapeutics, Inc. (ALRN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Zacks Investment Research
Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here’s Why You Should Buy the Stock Now
Tuesday Mar 14 2023 at 11:26
Aileron Therapeutics, Inc. (ALRN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock’s potential for a turnaround in the near term.
Zacks Investment Research
What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock
Thursday Dec 29 2022 at 13:32
Aileron Therapeutics, Inc. (ALRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research
Aileron Therapeutics, Inc. (ALRN) Moves to Buy: Rationale Behind the Upgrade
Friday Nov 04 2022 at 13:34
Aileron Therapeutics, Inc. (ALRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
GlobeNewsWire
Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference
Thursday Sep 22 2022 at 08:00
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) — Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation and participate in a fireside chat at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, at 3:30 p.m. ET in New York, New York.
PennyStocks
Penny Stocks to Buy on August 8th? 3 to Watch
Monday Aug 08 2022 at 06:00
Here’s what you need to know about buying penny stocks on August 8th The post Penny Stocks to Buy on August 8th? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks
How to Trade Penny Stocks in August 2022
Sunday Aug 07 2022 at 11:30
What you need to know about trading penny stocks in August The post How to Trade Penny Stocks in August 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
InvestorPlace
3 Oversold Biotech Stocks to Buy Now
Thursday May 19 2022 at 06:40
Looking for oversold biotech stocks? These three have all seen significant drops this year despite promising catalysts for the future.
GlobeNewsWire
Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Tuesday May 17 2022 at 07:00
BOSTON, May 17, 2022 (GLOBE NEWSWIRE) — Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 1:30 p.m. ET in Miami, FL.
Zacks Investment Research
Is Aileron Therapeutics (ALRN) Outperforming Other Medical Stocks This Year?
Thursday Apr 21 2022 at 11:19
Here is how Aileron Therapeutics, Inc. (ALRN) and Paragon 28, Inc. (FNA) have performed compared to their sector so far this year.
Zacks Investment Research
Is Aileron Therapeutics, Inc. (ALRN) Stock Outpacing Its Medical Peers This Year?
Tuesday Apr 05 2022 at 11:18
Here is how Aileron Therapeutics, Inc. (ALRN) and Becton Dickinson (BDX) have performed compared to their sector so far this year.
GlobeNewsWire
Aileron Therapeutics to Present at Upcoming Investor Conferences
Tuesday Jan 04 2022 at 08:45
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) — Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, is pleased to announce that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will provide a company overview and business update at the H.C. Wainwright BIOCONNECT Conference, which will be held virtually January 10th – 12th and the Emerging Growth Conference, which will be held virtually on January 5th. Details of the upcoming Aileron presentations are as follows:
GlobeNewsWire
Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924’s Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity
Thursday Oct 07 2021 at 09:22
— Aileron is currently developing ALRN-6924 as a novel, selective chemoprotective agent for patients with p53-mutated cancer undergoing chemotherapy — — Preclinical data demonstrated ALRN-6924’s activation of p21-induced cell cycle arrest in murine bone marrow cells and epithelial mucosa cells in the gastrointestinal (GI) tract —
GlobeNewsWire
Aileron Therapeutics Announces Presentation of New Preclinical Data at Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021
Thursday Sep 30 2021 at 16:30
BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) — Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today announced it will present new preclinical data at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstrating a potential secondary application of its novel, selective chemoprotective agent ALRN-6924 to also protect against radiation-induced toxicities.
Benzinga
Aileron Stock Is Trading Lower After Data Presentation For Chemoprotective Agent
Thursday Sep 16 2021 at 14:33
Aileron Therapeutics Inc (NASDAQ: ALRN) presented new clinical data at the European Society of Medical Oncology ( ESMO21 ) Virtual Congress 2021 for ALRN-6924, a chemoprotective agent. Aileron is developing ALRN-6924 to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects while preserving chemotherapy’s attack on cancer cells.
GlobeNewsWire
Aileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress 2021 Supporting ALRN-6924’s Best-in-Class Potential as a Chemoprotective Agent
Thursday Sep 16 2021 at 08:15
BOSTON, Sept. 16, 2021 (GLOBE NEWSWIRE) — Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today presented new clinical data at the European Society of Medical Oncology (ESMO) Virtual Congress 2021 supporting ALRN-6924’s best-in-class potential as a chemoprotective agent. The company presented final results from its completed Phase 1b trial of ALRN-6924 in patients with small cell lung cancer (SCLC) receiving second-line topotecan treatment, which demonstrated ALRN-6924’s ‘triple-play efficacy’ for the reduction of neutropenia, thrombocytopenia and anemia, as well as a reduction of platelet and red blood cell transfusions, as compared to historical controls. Aileron today also presented preliminary results from its ongoing Phase 1 pharmacology study of ALRN-6924, which confirmed 0.3 mg/kg as the optimal dose for ALRN-6924 and confirmed its novel p53 biomarker-driven mechanism of action, as well as its pharmacodynamic effects, including time to onset, magnitude and duration.
GlobeNewsWire
Aileron Therapeutics to Present New Clinical Data at ESMO Virtual Congress 2021 Supporting Novel, Selective Chemoprotective Agent ALRN-6924
Friday Sep 10 2021 at 08:30
BOSTON, Sept. 10, 2021 (GLOBE NEWSWIRE) — Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today announced two upcoming poster presentations at the European Society of Medical Oncology (ESMO) Virtual Congress 2021, which is being held September 16-21, 2021. In these posters, Aileron will present preliminary data from its ongoing Phase 1 study of ALRN-6924 in healthy volunteers and final data from its completed Phase 1b study of ALRN-6924 in patients with small cell lung cancer (SCLC) receiving second-line topotecan treatment. Aileron is developing ALRN-6924 to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects while preserving chemotherapy’s attack on cancer cells, an emerging concept known as chemoprotection. ALRN-6924, a first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle.
GlobeNewsWire
Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference
Tuesday Sep 07 2021 at 16:05
BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) — Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the upcoming H.C. Wainwright Virtual Global Investment Conference, taking place September 13 – 15, 2021. Dr. Aivado’s presentation will include an update on the company’s progress advancing ALRN-6924 as a selective chemoprotective agent for patients with p53-mutated cancers regardless of type of cancer or chemotherapy.
GlobeNewsWire
Aileron Therapeutics Presents Initial Findings from Ongoing Healthy Volunteer Study of ALRN-6924 at ISEH 50th Annual Scientific Meeting
Friday Aug 27 2021 at 07:45
BOSTON, Aug. 27, 2021 (GLOBE NEWSWIRE) — Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today announced a poster presentation showcasing initial findings from its ongoing study of ALRN-6924 in healthy volunteers at the International Society for Experimental Hematology (ISEH) 50th Annual Scientific Meeting, which is currently underway. The initial findings demonstrated that a 0.3 mg/kg dose of ALRN-6924 has been very well tolerated and resulted in p53-mediated induction of the cell cycle inhibitor p21 in healthy, normal bone marrow cells without concurrent induction of apoptosis. The poster can be viewed on Aileron’s website here.
GlobeNewsWire
Aileron Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
Wednesday Aug 11 2021 at 16:20
— —
GlobeNewsWire
Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2021
Thursday Jul 08 2021 at 08:15
BOSTON, July 08, 2021 (GLOBE NEWSWIRE) — Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, announced today that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at the William Blair Biotech Focus Conference 2021 at 3:00 p.m. ET on Thursday, July 15, 2021. Management will also be available for virtual 1×1 meetings from July 14-15.
Benzinga
Aileron Launches Early-Stage Study For Chemoprotective Candidate In Lung Cancer Settings
Thursday Jul 01 2021 at 13:39
Aileron Therapeutics Inc (NASDAQ: ALRN) has initiated Phase 1b trial of ALRN-6924 as a chemoprotective agent to treat patients with non-small cell lung cancer undergoing chemotherapy. Aileron plans to enroll 60 patients with advanced p53-mutated NSCLC undergoing treatment with first-line carboplatin plus pemetrexed with or without immune checkpoint inhibitors.
GlobeNewsWire
Aileron Therapeutics to be Added to the Russell Microcap® Index
Thursday Jun 24 2021 at 07:00
BOSTON, June 24, 2021 (GLOBE NEWSWIRE) — Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, announced today that it is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28, 2021.
GlobeNewsWire
Aileron Therapeutics to Host KOL Virtual Investor Event Discussing Opportunity for New Paradigm to Protect Cancer Patients from Chemotherapy-Induced Toxicities
Wednesday May 19 2021 at 07:00
— Fireside chat, moderated by Soumit Roy, Ph.D. of JonesTrading, will be held on Wednesday, May 26, 2021 at 11:00 am ET — — Featured speakers will include hematologist Alan List, M.D. and geriatric oncologist Lodovico Balducci, M.D. —
GlobeNewsWire
Aileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
Tuesday May 11 2021 at 16:18
— —
Seeking Alpha
Aileron Therapeutics: Solving Chemotherapy’s Toxicity
Friday Apr 30 2021 at 21:54
Chemotherapy is built into the treatment regime of nearly every cancer. However, chemotherapy’s well-known toxicity can lead to patient discontinuation and poor quality-of-life.
GlobeNewsWire
Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
Wednesday Mar 24 2021 at 16:36
— —
Seeking Alpha
Aileron Therapeutics: Low Cash Balance, Early Stage, But Scientific Premise Is Interesting
Wednesday Feb 10 2021 at 03:46
Aileron Therapeutics has a long history of not doing much. Its data is early stage, but the scientific theory is interesting.
InvestorPlace
7 Penny Stocks That Actually Have Buy Ratings
Wednesday Feb 03 2021 at 13:22
Many penny stocks are destined to fail, but these seven penny stocks may succeed. Wall Street has buy recommedations on them.
GlobeNewsWire
Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures, BVF Partners, L.P. and Maven Investment Partners
Monday Jan 11 2021 at 06:30
— Several existing Aileron investors, including Satter Medical Technology Partners and Lincoln Park Capital Fund, LLC, also participated in the offering — – Aileron plans to use net proceeds to undertake Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated advanced non-small cell lung cancer (NSCLC) —
Aileron Therapeutics Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Aileron Therapeutics’s Altman Z-score is -27.36 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Aileron Therapeutics Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in Aileron Therapeutics.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Aileron Therapeutics’s Income Quality of 1.13 is greater than its Industry Group of 0.69 (63.8% greater)
Aileron Therapeutics’s Income Quality of 1.13 is greater than its Major Industry Group of 0.71 (59.2% greater)
Aileron Therapeutics’s Income Quality of 1.13 is greater than its Sector of 0.75 (50.7% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Aileron Therapeutics’s Current Ratio of 11.66 is greater than its Industry Group of 4.76 (145.0% greater)
Aileron Therapeutics’s Current Ratio of 11.66 is greater than its Major Industry Group of 4.32 (169.9% greater)
Aileron Therapeutics’s Current Ratio of 11.66 is greater than its Sector of 2.6 (348.5% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-0.42 & -1.27)
Cannot compare a negative PE Ratio (-0.42 & -1.1)
Cannot compare a negative PE Ratio (-0.42 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Aileron Therapeutics’s PB Ratio of 0.56 is lower than its Industry Group of 1.34 (-58.2% lower)
Aileron Therapeutics’s PB Ratio of 0.56 is lower than its Major Industry Group of 1.4 (-60.0% lower)
Aileron Therapeutics’s PB Ratio of 0.56 is lower than its Sector of 1.62 (-65.4% lower)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Aileron Therapeutics’s ROE of -1.33 is lower than its Industry Group of -0.44 (-202.3% lower)
Aileron Therapeutics’s ROE of -1.33 is lower than its Major Industry Group of -0.38 (-250.0% lower)
Aileron Therapeutics’s ROE of -1.33 is lower than its Sector of -0.03 (-4333.3% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Aileron Therapeutics’s ROCE of -1.42 is lower than its Industry Group of -0.42 (-238.1% lower)
Aileron Therapeutics’s ROCE of -1.42 is lower than its Major Industry Group of -0.37 (-283.8% lower)
Aileron Therapeutics’s ROCE of -1.42 is lower than its Sector of -0.04 (-3450.0% lower)
Derived from SEC.GOV filing dataopen_in_new